Results and outcomes for patients with atrioventricular groove disruption after mitral valve surgery.


Journal

Perfusion
ISSN: 1477-111X
Titre abrégé: Perfusion
Pays: England
ID NLM: 8700166

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 28 2 2021
medline: 21 4 2022
entrez: 27 2 2021
Statut: ppublish

Résumé

Atrioventricular groove disruption (AVGD) is a rare and severe complication of mitral valve surgery (MVS). Current literature is limited to several case reports and series. Our aim was to analyze outcomes of patients with AVGD after MVS from our tertiary cardiac surgery center. Between June 2010 and January 2019, 18 patients suffering AVGD were identified in our institutional database and included in our retrospective observation. Preoperative, intraoperative and outcome data were analyzed using IBM SPSS Statistics. Late survival was estimated by using the Kaplan-Meier survival analysis. The mean age of the study population was 76 ± 5 years. Most common indication for MVS was an isolated mitral valve insufficiency (67%). Severe annular calcification was present in four patients (22%). Majority of implanted valves were biological prosthesis (78%). Due to the location, 72% suffered type I rupture. External repair was performed in 94% of all patients. Second look operation in regard of excessive mediastinal hemorrhage was necessary in 67% of patients. Mean hospital stay of the presented collective was 13 ± 11 days with an intra-hospital mortality of 56%. Late follow-up was obtained in eight patients at an average of 3.1 (1.6-5.7) years postoperatively. Mortality rates for AVGD after MVS are high. However, way of managing AVGD depends on the underlying type of rupture and should be evaluated in regard of the myocardial damage. Due to the rare occurrence, registry data might help to address more scientific value concerning therapeutic measures and outcomes of this severe complication.

Sections du résumé

BACKGROUND
Atrioventricular groove disruption (AVGD) is a rare and severe complication of mitral valve surgery (MVS). Current literature is limited to several case reports and series. Our aim was to analyze outcomes of patients with AVGD after MVS from our tertiary cardiac surgery center.
METHODS
Between June 2010 and January 2019, 18 patients suffering AVGD were identified in our institutional database and included in our retrospective observation. Preoperative, intraoperative and outcome data were analyzed using IBM SPSS Statistics. Late survival was estimated by using the Kaplan-Meier survival analysis.
RESULTS
The mean age of the study population was 76 ± 5 years. Most common indication for MVS was an isolated mitral valve insufficiency (67%). Severe annular calcification was present in four patients (22%). Majority of implanted valves were biological prosthesis (78%). Due to the location, 72% suffered type I rupture. External repair was performed in 94% of all patients. Second look operation in regard of excessive mediastinal hemorrhage was necessary in 67% of patients. Mean hospital stay of the presented collective was 13 ± 11 days with an intra-hospital mortality of 56%. Late follow-up was obtained in eight patients at an average of 3.1 (1.6-5.7) years postoperatively.
CONCLUSION
Mortality rates for AVGD after MVS are high. However, way of managing AVGD depends on the underlying type of rupture and should be evaluated in regard of the myocardial damage. Due to the rare occurrence, registry data might help to address more scientific value concerning therapeutic measures and outcomes of this severe complication.

Identifiants

pubmed: 33637032
doi: 10.1177/0267659121998938
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

284-292

Auteurs

Borko Ivanov (B)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Ilija Djordjevic (I)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Kaveh Eghbalzadeh (K)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Georg Schlachtenberger (G)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Stephen Gerfer (S)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Christopher Gaisendrees (C)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Elmar Kuhn (E)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Parwis Rahmanian (P)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Anton Sabashnikov (A)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Navid Mader (N)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Thorsten Wahlers (T)

Department of cardiothoracic surgery, University Hospital Cologne, Heart Centre Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH